Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.

Inclusion Criteria: * Age \>18 years * Suspected or proven bacterial infection requiring parenteral antibiotic therapy. * Organ replacement therapy (MARS, CVVHDF or HD) Exclusion Criteria: * Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents. * An expected survival of less than two days. * Known pregnancy * Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study * Doripenem as monotherapy for resistent species or fungal infections. * Other reasons opposing the study participation on the discretion of the investigators.